491 related articles for article (PubMed ID: 31089793)
1. Risk factors predicting graft-versus-host disease and relapse-free survival after allogeneic hematopoietic stem cell transplantation in relapsed or refractory non-Hodgkin's lymphoma.
Jeon YW; Yoon S; Min GJ; Park SS; Park S; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Cho SG
Ann Hematol; 2019 Jul; 98(7):1743-1753. PubMed ID: 31089793
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors on graft-versus-host disease-free and relapse-free survival after allogeneic hematopoietic stem cell transplantation for adults with acute leukemia.
Tan J; Wang Y; Yu SJ; Ma YY; Lei HY; Liu QF
Leuk Res; 2017 Aug; 59():1-7. PubMed ID: 28527401
[TBL] [Abstract][Full Text] [Related]
3. Refractory Graft-Versus-Host Disease-Free, Relapse-Free Survival as an Accurate and Easy-to-Calculate Endpoint to Assess the Long-Term Transplant Success.
Kawamura K; Nakasone H; Kurosawa S; Yoshimura K; Misaki Y; Gomyo A; Hayakawa J; Tamaki M; Akahoshi Y; Kusuda M; Kameda K; Wada H; Ishihara Y; Sato M; Terasako-Saito K; Kikuchi M; Kimura SI; Tanihara A; Kako S; Kanamori H; Mori T; Takahashi S; Taniguchi S; Atsuta Y; Kanda Y
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1521-1526. PubMed ID: 29476953
[TBL] [Abstract][Full Text] [Related]
4. Clinical Outcomes of Fludarabine and Melphalan With an 800 cGy Total Body Irradiation Conditioning Regimen in Patients With Refractory or Relapsed Aggressive Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Jeon YW; Yoon S; Min GJ; Park SS; Park S; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Cho SG
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):345-355.e7. PubMed ID: 31014757
[TBL] [Abstract][Full Text] [Related]
5. Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia.
Fan Q; Liu H; Liang X; Yang T; Fan Z; Huang F; Ling Y; Liao X; Xuan L; Xu N; Xu X; Ye J; Liu Q
J Hematol Oncol; 2017 Jul; 10(1):135. PubMed ID: 28676100
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease-Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Refractory/Relapsed Acute Leukemia.
Yan CH; Liu QF; Wu DP; Zhang X; Xu LP; Zhang XH; Wang Y; Huang H; Bai H; Huang F; Ma X; Huang XJ
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1311-1319. PubMed ID: 28483716
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic or autologous stem cell transplantation (SCT) for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma: a single-centre experience.
Nachbaur D; Oberaigner W; Fritsch E; Nussbaumer W; Gastl G
Eur J Haematol; 2001 Jan; 66(1):43-9. PubMed ID: 11168507
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma.
Doocey RT; Toze CL; Connors JM; Nevill TJ; Gascoyne RD; Barnett MJ; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Shepherd JD; Sutherland HJ; Voss NJ; Smith CA; Song KW
Br J Haematol; 2005 Oct; 131(2):223-30. PubMed ID: 16197454
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas.
Yoon JH; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Cho SG
Hematol Oncol; 2017 Mar; 35(1):17-24. PubMed ID: 25782369
[TBL] [Abstract][Full Text] [Related]
10. Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome.
Park SS; Jeon YW; Min GJ; Park S; Yahng SA; Yoon JH; Shin SH; Lee SE; Cho BS; Eom KS; Lee S; Kim HJ; Min CK; Cho SG; Lee JW; Kim YJ
Biol Blood Marrow Transplant; 2019 Jan; 25(1):63-72. PubMed ID: 30103018
[TBL] [Abstract][Full Text] [Related]
11. Factors Predicting Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Hematopoietic Cell Transplantation: Multivariable Analysis from a Single Center.
Solh M; Zhang X; Connor K; Brown S; Solomon SR; Morris LE; Holland HK; Bashey A
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1403-1409. PubMed ID: 27095692
[TBL] [Abstract][Full Text] [Related]
12. Partial T-cell depletion improves the composite endpoint graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic stem cell transplantation.
Simonetta F; Masouridi-Levrat S; Beauverd Y; Tsopra O; Tirefort Y; Koutsi A; Stephan C; Polchlopek-Blasiak K; Pradier A; Dantin C; Ansari M; Roosnek E; Chalandon Y
Leuk Lymphoma; 2018 Mar; 59(3):590-600. PubMed ID: 28679328
[TBL] [Abstract][Full Text] [Related]
13. Graft-
Devillier R; Eikema DJ; Dufour C; Aljurf M; Wu D; Maschan A; Kulagin A; Halkes CJM; Collin M; Snowden J; Renard C; Ganser A; Sykora KW; Gibson BE; Maertens J; Itäla-Remes M; Corti P; Cornelissen J; Bornhäuser M; Araujo MC; Ozdogu H; Risitano A; Socie G; De Latour RP
Haematologica; 2023 Sep; 108(9):2305-2315. PubMed ID: 36951165
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma.
Dann EJ; Daugherty CK; Larson RA
Bone Marrow Transplant; 1997 Sep; 20(5):369-74. PubMed ID: 9339751
[TBL] [Abstract][Full Text] [Related]
15. Donor Type and Disease Risk Predict the Success of Allogeneic Hematopoietic Cell Transplantation: A Single-Center Analysis of 613 Adult Hematopoietic Cell Transplantation Recipients Using a Modified Composite Endpoint.
Solh M; Zhang X; Connor K; Brown S; Morris LE; Holland HK; Bashey A; Solomon SR
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2192-2198. PubMed ID: 28864140
[TBL] [Abstract][Full Text] [Related]
16. Preemptive low-dose interleukin-2 or DLI for late-onset minimal residual disease in acute leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
Yuan XL; Tan YM; Shi JM; Zhao YM; Yu J; Lai XY; Yang LX; Huang H; Luo Y
Ann Hematol; 2021 Feb; 100(2):517-527. PubMed ID: 33128124
[TBL] [Abstract][Full Text] [Related]
17. [Allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia].
Wang Y; Liu KY; Xu LP; Liu DH; Chen H; Han W; Chen YH; Shi HX; Zhang YC; Wang JZ; Zhang XU; Chen Y; Huang XJ; Lu DP
Zhonghua Nei Ke Za Zhi; 2007 Nov; 46(11):903-6. PubMed ID: 18261271
[TBL] [Abstract][Full Text] [Related]
18. Second-line age-adjusted International Prognostic Index in patients with advanced non-Hodgkin lymphoma after T-cell depleted allogeneic hematopoietic SCT.
Perales MA; Jenq R; Goldberg JD; Wilton AS; Lee SS; Castro-Malaspina HR; Hsu K; Papadopoulos EB; van den Brink MR; Boulad F; Kernan NA; Small TN; Wolden S; Collins NH; Chiu M; Heller G; O'Reilly RJ; Kewalramani T; Young JW; Jakubowski AA
Bone Marrow Transplant; 2010 Sep; 45(9):1408-16. PubMed ID: 20062091
[TBL] [Abstract][Full Text] [Related]
19. Kinetics and Risk Factors of Relapse after Allogeneic Stem Cell Transplantation in Children with Leukemia: A Long-Term Follow-Up Single-Center Study.
Molina B; Gonzalez Vicent M; Herrero B; Deltoro N; Ruiz J; Perez Martinez A; Diaz MA
Biol Blood Marrow Transplant; 2019 Jan; 25(1):100-106. PubMed ID: 30142415
[TBL] [Abstract][Full Text] [Related]
20. Assessment of Individual versus Composite Endpoints of Acute Graft-versus-Host Disease in Determining Long-Term Survival after Allogeneic Transplantation.
Magenau J; Braun T; Gatza E; Churay T; Mazzoli A; Chappell G; Brisson J; Runaas L; Anand S; Ghosh M; Riwes M; Pawarode A; Yanik G; Reddy P; Choi SW
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1682-1688. PubMed ID: 30710686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
